Elevated circulating inflammatory biomarker levels in the SIRT1-NF-κB-sCD40L pathway in patients with acute

Chunjuan Chen1, Meiyi Zheng1,2, Wei Wang1

  • 1Department of Cardiology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China.

Annals of Medicine
|November 22, 2023
PubMed

Insights

Novel inflammatory biomarkers, SIRT1, NF-κB, and sCD40L, are elevated in acute myocardial infarction (AMI) patients. Combining NF-κB or sCD40L with troponin T (TNT) significantly improves AMI diagnostic accuracy.

Area of Science:

  • Cardiovascular Medicine
  • Inflammation Research
  • Biomarker Discovery

Background:

  • Inflammation is crucial in atherosclerosis development and progression.
  • The role of the SIRT1-NF-κB-sCD40L pathway in human atherosclerosis is not well understood.
  • This study investigates novel inflammatory mediators in acute myocardial infarction (AMI).

Purpose of the Study:

  • To evaluate changes in SIRT1, NF-κB, and sCD40L plasma levels in AMI patients.
  • To assess the clinical implications and diagnostic accuracy of these inflammatory mediators.
  • To explore the correlation between these biomarkers and cardiac troponin T (TNT).

Main Methods:

  • Collected peripheral arterial blood from 68 AMI patients and 20 controls.
  • Quantified plasma levels of SIRT1, NF-κB, and sCD40L using ELISA.
  • Analyzed correlations using Spearman's and Pearson's tests, and assessed diagnostic accuracy with ROC analysis.

Main Results:

  • AMI patients exhibited significantly higher plasma levels of SIRT1, NF-κB, and sCD40L compared to controls.
  • SIRT1, NF-κB, and sCD40L levels positively correlated with each other and with TNT levels in AMI patients.
  • Combining NF-κB or sCD40L with TNT significantly enhanced the diagnostic accuracy for AMI.

Conclusions:

  • Circulating levels of SIRT1, NF-κB, and sCD40L are elevated in AMI patients.
  • These novel biomarkers, particularly NF-κB and sCD40L when combined with TNT, improve AMI diagnostic accuracy.
  • Targeting the SIRT1/NF-κB/sCD40L axis presents a potential therapeutic strategy for AMI.
Abstract